首页> 美国卫生研究院文献>Journal of Clinical Medicine >Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
【2h】

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy

机译:对正在接受新辅助化疗的晚期卵巢癌患者的间隔减瘤手术中的根治性手术的反思

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study is to evaluate the effects on survival outcomes of the disease burden before interval debulking surgery (IDS), surgical complexity, and residual disease after IDS in advanced-stage ovarian cancer treated with neoadjuvant chemotherapy (NAC). We reviewed the data of 268 epithelial ovarian cancer patients who had received three or four cycles of NAC and undergone optimal resections through IDS. The Kaplan–Meier method and Cox regression analysis were used to assess the effects of disease burden (peritoneal cancer index (PCI)), degree of complexity of surgery (surgical complexity score/s (SCS)), and extent of residual disease. In no residual disease (R0) patients, those with intermediate/high SCS had shorter progression-free survival (PFS; = 0.001) and overall survival (OS; = 0.001) than patients with low SCS. An analysis of a subset of patients with R0 and low PCIs showed those with intermediate/high SCS had worse PFS and OS than patients with low SCS ( = 0.049) and OS ( = 0.037). In multivariate analysis, patients with R0 as a result of intermediate/high SCS fared worse than patients whose R0 was achieved by low SCS (PFS hazard ratio (HR) 1.80, 95% CI 1.05–3.10; OS HR 5.59, 95% CI 1.70–18.39). High PCIs at the time of IDS, high SCS, and residual disease signal poor prognoses for patients treated with NAC.
机译:这项研究的目的是评估在接受新辅助化疗(NAC)的晚期卵巢癌的间隔减瘤术(IDS)之前疾病负担生存结果,手术复杂性和IDS术后残余疾病的影响。我们回顾了268例上皮性卵巢癌患者的数据,这些患者接受了3或4个NAC周期并通过IDS进行了最佳切除。 Kaplan-Meier方法和Cox回归分析用于评估疾病负担(腹膜癌指数(PCI)),手术复杂程度(手术复杂性评分/秒(SCS))和残留疾病程度的影响。在无残留疾病(R0)的患者中,SCS中/高的患者的无进展生存期(PFS; = 0.001)和总体生存期(OS; = 0.001)比低SCS的患者要短。对一部分R0和低PCIs的患者进行的分析显示,中/高SCS患者的PFS和OS比低SCS(= 0.049)和OS(= 0.037)的患者差。在多变量分析中,由中/高SCS导致的R0患者的病情要比通过低SCS达到R0的患者更糟(PFS危险比(HR)1.80,95%CI 1.05–3.10; OS HR 5.59,95%CI 1.70) –18.39)。在接受NAC治疗的患者中,IDS时PCIs高,SCS高和残留疾病预后不良。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号